5-Fluorouracil nano-delivery systems as a cutting-edge for cancer therapy
- PMID: 36493619
- DOI: 10.1016/j.ejmech.2022.114995
5-Fluorouracil nano-delivery systems as a cutting-edge for cancer therapy
Abstract
5-Fluorouracil (5-FU) is amongst the most commonly used antimetabolite chemotherapeutic agents in recent decades. However, its low bioavailability, short half-life, rapid metabolism and the development of drug resistance after chemotherapy limit its therapeutic efficiency. In this study, 5-FU applications as an anti-cancer drug for treating diverse types of cancers (e.g. colon, pancreatic and breast) have been reviewed. Different approaches lately designed to circumvent the drawbacks of 5-FU therapy are described herein, including 5-FU-loaded lipid-based nanoparticles (NPs), polymeric NPs (both stimuli and non-stimuli responsive), carbon-based nanostructures and inorganic NPs. Furthermore, co-delivery systems of 5-FU with other drugs (e.g. paclitaxel, gelatin-doxorubicin and naproxen) have been reviewed, which aid to attain better bioavailability, higher effectiveness at a lower concentration and lower toxicity. This review provides researchers with the latest progress on 5-FU-loaded nanocarriers, which show great potential as an advanced tool for cancer therapy.
Keywords: 5-Fluorouracil; Cancer treatment; Drug delivery; Nanotechnology.
Copyright © 2022 Elsevier Masson SAS. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
